The S&P 500 Index ($SPX ) (SPY ) today is up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.081%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.40%. September E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.84%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.47%. September E-mini S&P futures...
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance...
Barchart Research What to Expect from KRYS Earnings KRYS Generated July 31, 2026 Current Price $341.12 EPS Estimate $$1.70 Consensus Rating Strong Buy Average Move 7.71% Can Krystal Biotech's Gene Therapy...
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August...
NEW YORK , July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:
The pharmaceutical industry is known for big risks and big rewards among investors; those willing to take on the risk may want to watch these firms.
VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic...
PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference...
$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK)...